Last 12 months
Inside the activity.
5 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 2 | 0 |
| Sep 2026 | 1 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 8 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 262,596 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 7 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 262,596 Underlying: Common Stock · 262,596 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 6 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 5 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
PurchaseCommon Stock | 1,522,500 | $10.00 | $15,225,000.00 |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · nonDerivative · entry 3 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ayabudge LLC Disclosed balance after: 20,452,504 Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantCommon Stock | 18,930,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · nonDerivative · entry 2 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ayabudge LLC Disclosed balance after: 18,930,004 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the"Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantCommon Stock | 1,148,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · nonDerivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,148,240 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the"Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:08 UTC |
Tente William EdwardChief Regulatory Officer
|
GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110520 · tm2125954-14_4seq1.xml · derivative · entry 6 Tente William Edward · CIK 0001878279 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:08 UTC |
Tente William EdwardChief Regulatory Officer
|
GrantStock Options (right to buy) · Derivative | 118,168 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110520 · tm2125954-14_4seq1.xml · derivative · entry 5 Tente William Edward · CIK 0001878279 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,168 Underlying: Common Stock · 118,168 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:08 UTC |
Tente William EdwardChief Regulatory Officer
|
GrantStock Options (right to buy) · Derivative | 91,908 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110520 · tm2125954-14_4seq1.xml · derivative · entry 4 Tente William Edward · CIK 0001878279 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,908 Underlying: Common Stock · 91,908 shares Expires 2025-12-11 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:08 UTC |
Tente William EdwardChief Regulatory Officer
|
GrantStock Options (right to buy) · Derivative | 91,908 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110520 · tm2125954-14_4seq1.xml · derivative · entry 3 Tente William Edward · CIK 0001878279 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,908 Underlying: Common Stock · 91,908 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:08 UTC |
Tente William EdwardChief Regulatory Officer
|
GrantStock Options (right to buy) · Derivative | 6,564 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001104659-21-110520 · tm2125954-14_4seq1.xml · derivative · entry 2 Tente William Edward · CIK 0001878279 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,564 Underlying: Common Stock · 6,564 shares Expires 2022-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:08 UTC |
Tente William EdwardChief Regulatory Officer
|
GrantCommon Stock | 52,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110520 · tm2125954-14_4seq1.xml · nonDerivative · entry 1 Tente William Edward · CIK 0001878279 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,519 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
DeAngelis Kiernan ThomasChief Medical Officer
|
GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110529 · tm2125954-18_4seq1.xml · derivative · entry 2 DeAngelis Kiernan Thomas · CIK 0001877848 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F3 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
DeAngelis Kiernan ThomasChief Medical Officer
|
GrantStock Options (right to buy) · Derivative | 99,576 | Not disclosed Strike: $8.49 | Not disclosed |
DisclosureSEC source: 0001104659-21-110529 · tm2125954-18_4seq1.xml · derivative · entry 1 DeAngelis Kiernan Thomas · CIK 0001877848 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,576 Underlying: Common Stock · 99,576 shares Expires 2030-06-11 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F1 · derivative.exercise_date: The first 1/3 of the grant, for 33,192 shares, is vested and exercisable. The next 1/3 of the grant will vest on April 20, 2022 and the final 1/3 will vest on April 20, 2023. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:13 UTC |
Ayabudge LLC10% owner
|
PurchaseCommon Stock | 1,522,500 | $10.00 | $15,225,000.00 |
DisclosureSEC source: 0001104659-21-110538 · tm2125954-22_4seq1.xml · nonDerivative · entry 2 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,452,504 Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:13 UTC |
Ayabudge LLC10% owner
|
GrantCommon Stock | 18,930,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110538 · tm2125954-22_4seq1.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,930,004 F1 · price: On August 26, 2021, Alpha Health care Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC |
Prichard Heather LedbetterChief Operating Officer
|
GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 6 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC |
Prichard Heather LedbetterChief Operating Officer
|
GrantStock Options (right to buy) · Derivative | 157,558 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 5 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,558 Underlying: Common Stock · 157,558 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC |
Prichard Heather LedbetterChief Operating Officer
|
GrantStock Options (right to buy) · Derivative | 78,779 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 4 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,779 Underlying: Common Stock · 78,779 shares Expires 2025-12-11 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC |
Prichard Heather LedbetterChief Operating Officer
|
GrantStock Options (right to buy) · Derivative | 78,779 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 3 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,779 Underlying: Common Stock · 78,779 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC |
Prichard Heather LedbetterChief Operating Officer
|
GrantStock Options (right to buy) · Derivative | 6,564 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 2 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,564 Underlying: Common Stock · 6,564 shares Expires 2022-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC |
Prichard Heather LedbetterChief Operating Officer
|
GrantCommon Stock | 2,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · nonDerivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 F1 · price: On August 26, 2021 , Alpha Health care Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub" ) and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Wallace Max N.Director
|
GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · derivative · entry 4 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Wallace Max N.Director
|
GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · derivative · entry 3 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Wallace Max N.Director
|
GrantStock Options (right to buy) · Derivative | 6,564 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · derivative · entry 2 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,564 Underlying: Common Stock · 6,564 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Wallace Max N.Director
|
GrantCommon Stock | 49,986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · nonDerivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,986 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:11 UTC |
Sebelius KathleenDirector
|
GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110533 · tm2125954-20_4seq1.xml · derivative · entry 2 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F1 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:11 UTC |
Sebelius KathleenDirector
|
GrantStock Options (right to buy) · Derivative | 39,389 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110533 · tm2125954-20_4seq1.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,389 Underlying: Common Stock · 39,389 shares Expires 2025-09-01 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F1 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 20:30 UTC |
Shukla RajivDirector · Chief Executive Officer · 10% owner
AHAC Sponsor LLC10% owner
|
OtherClass A Common Stock | 305,000 | $10.00 | $3,050,000.00 |
DisclosureSEC source: 0001213900-20-028048 · ownership.xml · nonDerivative · entry 1 Shukla Rajiv · CIK 0001709033 · Director · Chief Executive Officer · 10% owner AHAC Sponsor LLC · CIK 0001818390 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 305,000 F1 · kind: Consists of 305,000 placement units purchased by AHAC Sponsor LLC ("Sponsor") for $10.00 per unit in a private placement transaction with the registrant. Each such unit consists of one share of Class A common stock and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment. F2 · ownership.nature: Sponsor is the record holder of the securities reported herein. Mr. Rajiv Shukla is the managing member of the Sponsor and may be deemed the beneficial owner of the shares held by the Sponsor. Mr. Shukla disclaims beneficial ownership over any securities in which he does not have a pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.